We’ve found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
Charles River Laboratories International Investment Narrative Recap
To own Charles River Laboratories, you need to believe its position in outsourced preclinical research can translate a complex, service heavy model into improving profitability despite recent revenue softness, biotech funding uncertainty and competition. The CEO succession to long serving COO Birgit Girshick appears thoughtfully staged and, by itself, does not materially change the near term focus on converting backlog, stabilizing DSA demand and containing margin pressure from pricing and cancellations.
The May 2025 announcement of a wide ranging strategic review, coupled with Elliott Investment Management joining as a cooperating investor, is the clearest recent signal that Charles River’s board is already probing options to improve growth, returns and capital allocation. Against that backdrop, the Girshick transition looks more like the governance and leadership continuity piece of a broader reset than a standalone catalyst, with execution on cost savings and organic demand recovery still doing most of the heavy lifting.
But even with this orderly succession plan, investors should be aware that rising cancellations and a book to bill below 1x could…
Read the full narrative on Charles River Laboratories International (it’s free!)
Charles River Laboratories International’s narrative projects $4.4 billion revenue and $483.2 million earnings by 2028. This requires 2.8% yearly revenue growth and a $552.4 million earnings increase from -$69.2 million today.
Uncover how Charles River Laboratories International’s forecasts yield a $188.93 fair value, a 14% downside to its current price.
Exploring Other Perspectives
CRL 1-Year Stock Price Chart
Two fair value estimates from the Simply Wall St Community span roughly US$188.93 to US$251.05 per share, showing how far apart individual expectations can be. You should weigh these against the current dependence on backlog conversion amid softer organic bookings, which could influence how quickly any perceived mispricing is resolved.
Explore 2 other fair value estimates on Charles River Laboratories International – why the stock might be worth as much as 14% more than the current price!
Build Your Own Charles River Laboratories International Narrative
Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.
Contemplating Other Strategies?
Our daily scans reveal stocks with breakout potential. Don’t miss this chance:
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com